Over the past three months, Corbus Pharmaceuticals Holdings Inc. [CRBP] ended the trading day at $1.20 and exhibited a change of 0.00% with a 24 hour trading and reached upto the volume of 5.49M compared to its recorded trading volume of 3.7 million. CRBP generated a 1 year amount change with -72.97%. Though for Principal markets a year is counted as a long time period. By having a look at the most recent performance of this stock, in the last week its amount moved by -1.64% with an amount shift of 22.50% over the last month.

On 12, November 2020, Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference. According to news published on Yahoo Finance, Fireside chat with live audio webcast on Thursday, November 19th at 12:35 PM EST.

Analyst Birdseye View:

The most recent analyst activity for Corbus Pharmaceuticals Holdings Inc. [NASDAQ:CRBP] stock was on September 08, 2020, when it was Downgrade with a Sector perform rating from RBC Capital Mkts. Before that, on September 08, 2020, ROTH Capital Recapitulated a Neutral rating and elevated its amount target to $3. On September 08, 2020, Jefferies Downgrade a Hold rating and plunged its price target on this stock from $18 to $2.50. On September 08, 2020, BTIG Research Downgrade a Neutral rating. On July 07, 2020, ROTH Capital Initiated a Buy rating and increased its price target to $40. On June 17, 2020, BTIG Research Initiated a Buy rating and boosted its amount on this stock to $22. On March 26, 2020, Nomura Initiated a Buy rating and boosted its target amount on this stock to $12.

In the past 52 weeks of trading, this stock has oscillated between a low of $0.91 and a peak of $9.78. Right now, according to Wall Street analyst the average 12-month amount target is $1.88. At the most recent market close, shares of Corbus Pharmaceuticals Holdings Inc. [NASDAQ:CRBP] were valued at $1.20.

FUNDAMENTAL ANALYSIS

Corbus Pharmaceuticals Holdings Inc. [NASDAQ:CRBP] most recently reported quarterly sales of 1.23 billion, which represented growth of -53.80%. This publicly-traded organization’s revenue is $256,337 per employee, while its income is -$506,764 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -148.66, -424.29, -375.38 and -342.06 respectively.

The Principal structure of this organization shows its whole liability to whole principal at 60.54 and the whole liability to whole assets at 19.22. It shows enduring liability to the whole principal at 51.89 and enduring liability to assets at 0.16 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 1.1533 points at 1st support level, the second support level is making up to 1.1067. But as of 1st resistance point, this stock is sitting at 1.2633 and at 1.3267 for 2nd resistance point.

Corbus Pharmaceuticals Holdings Inc. [CRBP] reported its earnings at -$0.42 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.42/share signifying the difference of 0 and 0.00% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.52 calling estimates for -$0.39/share with the difference of -0.13 depicting the surprise of -33.30%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Corbus Pharmaceuticals Holdings Inc. [NASDAQ:CRBP] is 2.10. Likewise, the Quick ratio is also the same, showing Cash ratio at 0.91. Now if looking for a valuation of this stock’s amount to sales ratio it’s 9.65 and it’s amount to book ratio is 57.35.

Insider Stories

The most recent insider trade was by Cohen Yuval, Chief Executive Officer, and it was the purchase of 4240.0 shares on Nov 11. Millian Craig Stuart, the Chief Commercial Officer, completed a purchase of 2000.0 shares on Mar 17. On Mar 17, Cohen Yuval, Chief Executive Officer, completed a purchase of 4300.0 shares.